Radiation Oncology Department, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.
Department of Medical Science, Universitat de Girona, Girona, Spain.
Cancer Med. 2023 Jun;12(11):12343-12353. doi: 10.1002/cam4.5935. Epub 2023 Apr 19.
To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs.
Population-based study of MZL collected in the Girona Cancer Registry, 1994-2018. Sociodemographic data, tumor location, and stage were obtained from clinical records. Crude (CR) and age-adjusted (ASR ) incidence rates expressed per 100,000 person-years (p-y) were calculated. Joinpoint regression models were used for the trend analysis according to the MZL group. Five-year observed and net survival were analyzed.
A total of 472 MZLs were included, 44 (9.3%) were nodal, 288 (61.0%) extranodal, 122 (25.9%) splenic, and the rest (n = 18) MZL, NOS. The CR for the MZL was 2.89 × 100,000 p-y (95% CI: 2.63-3.15), the ASR was 3.26 × 100,000 p-y (95% CI: 2.97-3.57), and the annual percentage change (APC) was 1.6 (95% CI: 0.5-2.7). The ASR for nodal MZL was 0.30 × 100,000 p-y (95% CI: 0.22-0.41) and showed an APC of 2.9% (95% CI: -16.4-26.6). For extranodal MZL, the ASR was 1.98 × 100,000 p-y (95% CI: 1.76-2.23) and the APC was -0.4 (95% CI: -2.0-1.2). The most frequent locations of this type of MZL were the gastric (35.4%), skin (13.2%), and respiratory system (11.8%). The ASR of the splenic MZL was 0.85 (95% CI: 0.71-1.02) with an APC of 12.8 (95% CI: 2.5-24.0). The 5-year net survival of MZL was 82.1% (95% CI: 76.3-86.5).
This study reveals differences in the incidence and trend of the incidence of MZL according to the subgroup, showing a significant increase in the overall MZL mainly due to splenic MZL type.
分析赫罗纳地区边缘区淋巴瘤(MZL)的发病率、发病趋势和生存率,并描述结外 MZL 病例的发病位置。
本研究是一项基于人群的 MZL 病例收集研究,数据来自赫罗纳癌症登记处,时间范围为 1994 年至 2018 年。从临床记录中获取人口统计学数据、肿瘤位置和分期。计算每 100,000 人年(p-y)的粗发病率(CR)和年龄调整发病率(ASR)。根据 MZL 组使用 Joinpoint 回归模型进行趋势分析。分析 5 年观察生存率和无进展生存率。
共纳入 472 例 MZL,其中 44 例(9.3%)为结内,288 例(61.0%)为结外,122 例(25.9%)为脾,其余 18 例(12.2%)为 MZL,NOS。MZL 的 CR 为 2.89×100,000 p-y(95%CI:2.63-3.15),ASR 为 3.26×100,000 p-y(95%CI:2.97-3.57),年变化百分比(APC)为 1.6(95%CI:0.5-2.7)。结内 MZL 的 ASR 为 0.30×100,000 p-y(95%CI:0.22-0.41),APC 为 2.9%(95%CI:-16.4-26.6)。对于结外 MZL,ASR 为 1.98×100,000 p-y(95%CI:1.76-2.23),APC 为-0.4(95%CI:-2.0-1.2)。这类 MZL 最常见的发病位置是胃(35.4%)、皮肤(13.2%)和呼吸系统(11.8%)。脾 MZL 的 ASR 为 0.85(95%CI:0.71-1.02),APC 为 12.8(95%CI:2.5-24.0)。MZL 的 5 年无进展生存率为 82.1%(95%CI:76.3-86.5)。
本研究根据亚组分析了 MZL 的发病率和发病趋势的差异,结果显示总体 MZL 发病率显著增加,主要是由于脾 MZL 类型所致。